Public consultation on interim decisions to amend the Poisons Standard - ACMS, ACCS & Joint ACMS-ACCS NOVEMBER, 2023
Feedback updated 22 May 2024
We asked
From 3 April 2024 to 17 April 2024, we sought submissions from the public on the Delegate’s interim decisions on substances previously discussed at the November 2023 meetings of the Advisory Committees on Medicines and Chemicals Scheduling. Respondents were given the choice to indicate their support or opposition to the proposed amendments using survey buttons, with or without a written submission.
You said
A total of 32 submissions were received through the consultation, 21 from individuals and 11 from organisations. A breakdown of the submissions can be found below.
ASTODRIMER SODIUM: 11 submissions were received, 10 in full support, and 1 in partial support of the interim decision. Of these, 10 provided a written component, 9 written submissions in support, and 1 in partial support.
BILASTINE: 1 submission was received, which was in full support of the interim decision. No written component was included.
BPC-157: 1 submission was received, which was in full support of the interim decision. No written component was included.
GLYCOPYRRONIUM: 2 submissions were received, which were in opposition of the interim decision. All submissions included a written component.
METHENAMINE: 4 submissions were received, 1 in full support, 2 in partial support, and 1 in opposition of the interim decision. Of these, 3 provided a written submission, 2 were in partial support and 1 was in opposition of the interim decision.
NARATRIPTAN: 1 submission was received, which was in full support of the interim decision. No written component was included.
PARACETAMOL: 6 submissions were received, 2 in full support, 1 in partial support, and 3 in opposition of the interim decision. Of these, 3 provided a written submission, 1 in support, 1 in partial support and 1 in opposition of the interim decision.
ANIMAL BLOOD PRODUCTS: 1 submission which included a written component was received, the submission was in support of the interim decision.
BILE ACIDS: 1 submission which included a written component was received, the submission was in opposition of the interim decision.
ADRENALINE: 2 submissions were received, which were in full support of the interim decision. No written component was included.
BENZOIC ACID: 2 submissions were received, which were in full support of the interim decision. Of these, 1 submission included a written component.
MELOXICAM: 11 submissions were received, which were all in full support of the interim decision. Of these, 5 provided a written component.
PALMITOYLETHENOLAMIDE (PEA): 2 submissions were received, which were both in support of the interim decision. All submissions included a written component.
CAMPROMORELIN: No submissions were received.
We did
The Delegates considered all submissions prior to making their final decision. The final decisions on the proposed amendments to the Poisons Standard were published on 22 May 2024.
Published responses
View submitted responses where consent has been given to publish the response.
Overview
Interim decisions regarding substances discussed at the expert advisory meetings.
This consultation is for interim decisions made in relation to substances that were discussed at the NOVEMBER 2023 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).
The interim decisions published below may differ from the initial proposal. Please read through the proposed interim decisions which can be accessed through the links below and are available on the consultation page for your convenience.
Once you are familiar with the interim decision, please provide your comments and votes in relation to the interim decision.
The closing date for this consultation is close of business 17 APRIL 2024. All submissions received by the deadline will be considered by the delegate before they make an interim decision.
The interim decisions under consultation are detailed in the Public notice of interim decisions NOVEMBER 2023 which can be accessed below:
Substances for which public comment is sought:
ACMS:
ASTODRIMER SODIUM
BILASTINE
BPC-157
GLYCOPYRRONIUM
METHENAMINE
NARATRIPTAN
PARACETAMOL
ACCS:
ANIMAL BLOOD PRODUCTS
BILE ACIDS
JOINT ACMS-ACCS:
ADRENALINE
BENZOIC ACID
MELOXICAM
PALMITOYLETHANOLAMIDE (PEA)
DELEGATE-ONLY DECISION:
CAPROMORELIN
What happens next
All public submissions will be published on the TGA website at Public submissions on scheduling matters, unless marked confidential or indicated otherwise in the submission information (see Privacy and your Personal information).
Public submissions are an important part of the process for amending the Poison Standard, and are published on the TGA website using the consultation hub. Submissions by the public may not reflect the views of the Department of Health and Aged Care or TGA. Published submissions should not be taken as being endorsed by the Department or TGA.
Following consideration of public submissions received before the closing date and advice from the expert advisory committees, decisions on the proposed amendments are anticipated to be published as final decisions on the TGA website: Scheduling delegate's final decisions at a later date.
Audiences
- Aboriginal and Torres Strait Islander People
- Seniors
- Men
- Women
- Carers and guardians
- Families
- Parents
- Young people
- Academics
- Non-government organisations
- State government agencies
- Commonwealth agencies
- Health professionals
- Health workforce
- General public
- Community groups
- Businesses
- Contracted Service Providers
- Aged care service providers
- Aged care workforce
- Aged care professionals
- BPRU staff
- Graduates
- Online and Publications staff
- Secretariat
- PCCD
- Health staff
- HPRG (TGA) Staff
- Prescription medicines
- Complementary medicines
- Over-the-counter medicines
- Medical Devices & IVDs
- Biologicals
- Other
Interests
- Policy Development
Share
Share on Twitter Share on Facebook